Genentech, Inc., Infectious Diseases, South San Francisco, California, USA
Genentech, Inc., Biochemical and Cellular Pharmacology, South San Francisco, California, USA.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01142-18. Print 2018 Nov.
There is a critical need for new antibacterial strategies to counter the growing problem of antibiotic resistance. In Gram-negative bacteria, the outer membrane (OM) provides a protective barrier against antibiotics and other environmental insults. The outer leaflet of the outer membrane is primarily composed of lipopolysaccharide (LPS). Outer membrane biogenesis presents many potentially compelling drug targets as this pathway is absent in higher eukaryotes. Most proteins involved in LPS biosynthesis and transport are essential; however, few compounds have been identified that inhibit these proteins. The inner membrane ABC transporter MsbA carries out the first essential step in the trafficking of LPS to the outer membrane. We conducted a biochemical screen for inhibitors of MsbA and identified a series of quinoline compounds that kill through inhibition of its ATPase and transport activity, with no loss of activity against clinical multidrug-resistant strains. Identification of these selective inhibitors indicates that MsbA is a viable target for new antibiotics, and the compounds we identified serve as useful tools to further probe the LPS transport pathway in Gram-negative bacteria.
目前迫切需要新的抗菌策略来应对日益严重的抗生素耐药问题。在革兰氏阴性菌中,外膜(OM)为抗生素和其他环境侵害物提供了保护屏障。外膜的外叶主要由脂多糖(LPS)组成。外膜生物发生提供了许多有吸引力的潜在药物靶点,因为这条途径在高等真核生物中不存在。参与 LPS 生物合成和运输的大多数蛋白质都是必需的;然而,已经确定的抑制这些蛋白质的化合物很少。内膜 ABC 转运蛋白 MsbA 进行 LPS 向外膜运输的第一个必需步骤。我们进行了 MsbA 抑制剂的生化筛选,并鉴定出一系列喹啉化合物,通过抑制其 ATP 酶和运输活性来杀死细菌,对临床多药耐药株没有失去活性。这些选择性抑制剂的鉴定表明 MsbA 是新型抗生素的一个可行靶点,我们鉴定的化合物可作为进一步探究革兰氏阴性菌 LPS 运输途径的有用工具。